Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Respiri Limited ( (AU:RSH) ) just unveiled an announcement.
Respiri Limited has completed the acquisition of Orb Health, marking a strategic move to enhance its presence in the connected and chronic care health market in the United States. This acquisition not only accelerates Respiri’s market commercialization efforts but also results in significant operational cost savings and improved service offerings, benefiting both existing and potential clients. Additionally, the company has undergone restructuring, with Nicholas Smedley transitioning to Non-executive Chairman, signaling a focused push into the US market.
More about Respiri Limited
Respiri Limited is a leading company in the healthcare industry, specializing in medical devices and MedTech. It focuses on transforming healthcare delivery in the US by offering innovative solutions for chronic disease management. Their flagship product, the wheezo® medical device, is an FDA-approved tool for respiratory disorder detection, highlighting their expertise in remote healthcare solutions.
YTD Price Performance: -13.46%
Average Trading Volume: 253,500
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $62.96M
Find detailed analytics on RSH stock on TipRanks’ Stock Analysis page.
